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In 1990 two parallel randomized controlled multicentre clinical
trials were initiated to compare the effects of conventional radio-
therapy, a daily dose given 5 days per week for 6–6.5 weeks,
versus continuous hyperfractionated accelerated radiation therapy
(CHART), given 3 times daily over 12 consecutive days (including
weekends). The trials were conducted in patients with locally
advanced non-small-cell lung cancer (NSCLC) and locally
advanced head and neck cancer. Between 1 April 1990 and 31
March 1995, a total of 563 patients with NSCLC and 918 with
head and neck cancer were entered by 13 centres. The results of
these trials on the clinical endpoints have been published (Dische
et al, 1997; Saunders et al, 1997).
Patients randomized on or after 1 October 1990 and before 1
December 1993 in the ten UK centres were asked to complete both
a Rotterdam Symptom Checklist (De Haes et al, 1990) and a
Hospital Anxiety and Depression Scale (Zigmond and Snaith,
1983) on a total of ten occasions, in order to assess quality of life
(QOL) symptoms. The results of the analysis of the patient-
completed QOL measurements for the NSCLC trial have been
presented (Bailey et al, 1997) and published (Bailey et al, 1998).
The most recent published clinical results of the analysis for the
head and neck trial found that there was no evidence of a differ-
ence between patients treated with CHART and conventional
treatment in terms of any of the major clinical outcome measures
of survival, freedom from metastases, locoregional control and
disease-free interval (Dische et al, 1997). Given these results an
important question remains: Is there any difference in the quality
of life between the two treatments? In this paper we report the
results of the comparison of CHART and conventionally treated
patients in terms of patient-reported physical and psychological
symptoms.
There are problems concerned with the analysis of QOL data
due to its multidimensional and longitudinal nature and the
possibility of informed censoring through missing information.
Solutions have been suggested, but presently none satisfy all of
these issues in combination. In this analysis the aim throughout
has been to keep the methods of analysis simple (Cox et al, 1992)
in order to minimize the number of assumptions made and to
ensure that the presentation and interpretation of the results are as
clear as possible. To do this each individual symptom was consid-
ered separately and the data were analysed separately for short-
term (first 3 months) and long-term effects (1 year and 2 years).
Such an approach also corresponds to clinically relevant times,
representing periods of acute and late morbidity. For the short-
term analysis a subject-specific approach and a group-based
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Summary The randomized multicentre trial of continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional
radiotherapy in patients with advanced head and neck cancer showed no good evidence of a difference in any of the major clinical outcomes
of survival, freedom from metastases, loco-regional control and disease-free survival. Therefore an assessment of the effect of treatment on
physical and psychological symptoms is vital to balance the costs and benefits of the two treatments. A total of 615 patients were asked to
complete a Rotterdam Symptom Checklist and the Hospital Anxiety and Depression Scale, which cover a variety of physical and
psychological symptoms, at a total of ten time points. The data consisted of short-term data (the initial 3 months) and long-term data (1 and 2
years). The short-term data was split into an exploratory data set and a confirmatory data set, and analysed using subject-specific and group-
based methods. Differences were only claimed if hypotheses generated in the exploratory data set were confirmed in the confirmatory data
set. The long-term data was not split into two data sets and was analysed using a group-based approach. There was evidence of significantly
worse symptoms of pain at day 21 in those treated with CHART and significantly worse symptoms of cough and hoarseness at 6 weeks in
those treated conventionally. There was also evidence to suggest a higher degree of decreased sexual interest at 1 year and sore muscles at
2 years in those treated with conventional radiotherapy. There is no clear indication that one regimen is superior to the other in terms of
‘quality of life’, generally the initially more severe reaction in the CHART group being offset by the longer duration of symptoms in the
conventionally treated group. © 1999 Cancer Research Campaign
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was good evidence of a large difference between the two treat-
ments over the first 3 months. To address the problem of multiple
comparisons the short-term data were split into two data sets, one
to generate hypotheses and one to prospectively test them. For the
long-term analysis a group-based approach was adopted to address
the question of whether there was good evidence of a large differ-
ence between the two treatments for those patients surviving to 1
year and those surviving to 2 years. It was not possible to consider
longer term data as it was only collected for the first 30 months
following start of radiotherapy. A subject-specific approach was
not appropriate for the long-term data due to the small number of
patients with information at these time points. It should be empha-
sized that the primary aim of the analysis was to assess the
evidence for differences in reported symptoms between CHART
and conventional radiotherapy, rather than to investigate variation
over time in individual treatment groups.
METHODS
The methods used in this analysis are described in detail in the
NSCLC paper (Bailey et al, 1998) and therefore we only give them
in summary in this paper.
Assessment of symptoms
To assess symptoms of quality of life, the Rotterdam Symptom
Checklist (RSCL) (De Haes et al, 1990) and the Hospital Anxiety
and Depression Scale (HADS) (Zigmond and Snarth, 1983) were
both used. The RSCL is a patient-completed questionnaire
designed to be used in studies of cancer patients. It comprises 30
core symptoms covering two domains (physical and psycholog-
ical), to which four symptoms relevant to this patient group were
added (cough, coughing up blood, hoarseness and restlessness). In
addition, the questions on low back pain and abdominal ache were
replaced by pain. Patients recorded their overall experience of
these 33 symptoms during the previous week using a 4-point cate-
gorical scale (0 = not at all, 1 = a little, 2 = moderately, 3 = very
much). The HADS is a 14-item self-rating questionnaire, seven
items concerning anxiety and seven depression, again using a 4-
point categorical scale (0–3). The seven-item scores (0–3) of the
anxiety questions were summed giving an overall score for anxiety
of between 0 and 21; the same calculation was performed to obtain
a score for depression. These scores were used to determine
whether a patient, during the previous week, was considered
normal (a score of 0–7), having borderline clinical anxiety or
depression (a score of 8–10), or as a probable clinical case (a score
of 11–21). In our analysis, patients only had a score for anxiety or
depression at a particular assessment if they had responded to all
seven relevant questions.
Patients were asked to complete these questionnaires before the
start of treatment, at day 21, day 28, week 6 and at 3, 6, 12, 18, 24
and 30 months from the date of start of radiotherapy. These time
points were selected to coincide with the collection of the clinical
data and to assess patients when the side-effects of treatment were
likely to be most severe. All data were collected by designated
research nurses at each of the centres; each centre was visited to
ensure that the research nurses and data managers were familiar
with the procedures for data collection and handling of patient
queries. Completed questionnaires were sent to the Medical
Research Council Cancer Trials Office in Cambridge for checking
and processing and were managed using the COMPACT program
(COMPACT Steering Committee, 1996) and analysed using SAS
(1989).
Analysis
The data were analysed separately for short-term symptoms and
long-term symptoms to circumvent the problem of missing data
(Cox et al, 1992). The proportion of missing information was
small during the first 3 months (short-term).
Short-term
The subject-specific approach is a method which considers the
individual as the basic ‘unit’ of analysis. For each individual the
severity of each symptom was plotted against the assessment time
and then the area under the curve (AUC) was calculated. The total
AUC score was standardized by dividing by the number of days
between the first assessment and the final assessment, resulting in
the standardized area under the curve (SAUC) being calculated for
each patient, for each symptom. The SAUC can be interpreted as a
type of weighted average of the responses over time for a
symptom. The assumptions that were made in the AUC approach
of analysis were as follows:
1. Patients who had data for a symptom missing consistently after
a certain time point but for whom data were expected were not
distinguished from patients who had died and thus for whom
no data were expected;
2. Patients who had no data or only data at a single assessment
for a symptom could not contribute to the analysis and were
omitted;
3. Patients with missing data at the pretreatment assessment were
excluded;
4. If a single data point was missing between two time points the
missing value was imputed, a linear trend between time points
was assumed. However, if two or more consecutive data points
were missing for a particular symptom the patient was omitted
from the analysis.
The Mann–Whitney test (Altman, 1991) allowing for ties was
used to formally test for a difference in SAUC scores between
treatments for each symptom.
The group-based approach considers the proportion of all
patients in each treatment group falling into each symptom cate-
gory over time. This summary of the data gives an impression of
the severity of each symptom at each specific time in the trial, and
can be useful in highlighting changes in the distribution of patient
response at particular times during follow-up. For each individual
symptom the proportion of patients with moderate/severe values (or
borderline/case for HADS) at each assessment were plotted and
compared at each time point between treatments using a c2 test.
To address the problem of multiple comparisons because of the
many symptoms studied, we randomly split the short-term data
into two subsets. This allowed hypotheses to be generated from the
first data set ‘the exploratory data set’ and prospectively tested on
the second data set ‘the confirmatory data set’. Differences were
only claimed if they were ‘confirmed’ in this second data set; the
reasoning for this split is discussed more fully in the NSCLC paper
(Bailey et al, 1998). For the short-term group-based analysis the
number of patients in both the exploratory and confirmatory data
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ments of 20% or more at any one time point (50% vs 70%, two-
sided, power = 90%, a = 5%).
Long-term
For the long-term symptom data at 1 year and 2 years, the analysis
is performed conditionally on those patients who have survived to
those time points and is therefore independent of any missing data
(because of death) up to these time points. The number of patients
with long-term data is diminished compared to those with short-
term data and so the data were not split into an exploratory and
confirmatory data set. Instead a group-based analysis was adopted
for all patients with data at 1 and 2 years in order to investigate
treatment differences for those patients surviving to these times. It
should be noted that as a consequence there were no clear
hypotheses to be tested and thus these analyses were largely
exploratory in nature.
RESULTS
Patients
Of the 918 patients recruited into the trial, 615 were entered into
the QOL study (373 CHART, 242 conventional radiotherapy). It
should be noted that there was a 3:2 randomization in favour of
CHART. Details of the patient characteristics for these 615
patients were broadly similar to the total data set of all 918 patients
(Dische et al, 1997). Compliance was very good, with 87% of the
total number of expected questionnaires received, and 78% ‘fully’
completed, disregarding the symptom decreased sexual interest.
Pretreatment symptoms from the RSCL
Pretreatment data were available for 32 of the 33 items on the
RSCL for at least 95% of patients (582/615), the exception being
decreased sexual interest, where data were available for only 79%
of patients (488/615). The frequency and severity of symptoms
which were reported by patients before the start of treatment are
shown in Figure 1, in decreasing order of prevalence. Using a
Mann–Whitney test it was found that there was no good evidence
that the distribution of severity was different in the two treatment
groups.
Pretreatment symptoms from the HADS
The percentage of patients with normal, borderline or case anxiety
and depression at the pre-treatment assessment are given in Table
1. The proportion of patients with borderline or case anxiety and
depression were similar in the two treatments. Differences
between the sexes are discussed later.
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Figure 1 Percentage of patients reporting symptoms from the RSCL before start of treatment (all patients)
Table 1 Pretreatment HADS anxiety and depression scores, split by sex (all
patients)
Overall (%) Male (%) Female (%)
Anxiety
Normal (0–7) 410 (71) 326 (77) 84 (56)
Borderline (8–10) 87 (15) 58 (14) 29 (19)
Case (11–21) 77 (13) 41 (10) 36 (24)
Patients with a score 574 (93) 425 (94) 149 (92)
Total patients 615 453 162
Depression
Normal (0–7) 518 (89) 391 (90) 127 (85)
Borderline (8–10) 33 (6) 24 (6) 9 (6)
Case (11–21) 31 (5) 18 (4) 13 (9)
Patients with a score 582 (95) 433 (96) 149 (92)
Total patients 615 453 162Random data split
The data were then randomly split into an exploratory data set
consisting of 307 patients (184 CHART, 123 conventional) and a
confirmatory data set consisting of 308 patients (189 CHART, 119
conventional).
Pretreatment comparisons
Symptoms from the RSCL
The proportion of patients reporting moderate or severe symptoms
in the exploratory data set and the confirmatory data were reason-
ably well balanced. Exceptions included a greater proportion of
patients reporting moderate or severe symptoms in the confirma-
tory data set for the symptoms of worrying (24% vs 33%, P =
0.013) and nervousness (14% vs 20%, P = 0.047) and a greater
proportion in the exploratory data set for the symptom of cough
(23% vs 16%, P = 0.038). Within each data set the proportion of
patients reporting moderate or severe symptoms were reasonably
well balanced between the treatments, although in the exploratory
group there was some evidence of larger proportions in the
conventional treatment group for the symptoms of hoarseness
(31% vs 42%, P = 0.047), cough (18% vs 31%, P = 0.010),
despondent feelings (11% vs 20%, P = 0.038) and shortness of
breath (10% vs 19%, P = 0.030). In the confirmatory data set there
was some evidence of a greater proportion of patients reporting
moderate or severe symptoms in the conventional treatment group
for the symptom of despondent feelings (12% vs 21%, P = 0.040).
Anxiety and depression from HADS
There was no evidence of a difference in the proportion of patients
with borderline or case anxiety, or borderline or case depression,
before the start of treatment in the exploratory data set when
compared to the confirmatory data set. Within each exploratory
and confirmatory data set, there was no evidence of a difference
between the treatments.
Exploratory data set
Subject-specific analysis
Short-term symptoms from the RSCL. For all but one of the
33 symptoms, analyses were based on at least 274 patients, the
exception being the symptom decreased sexual interest which was
based on 209 patients.
A summary of the results for all 33 symptoms from the RSCL
are presented in Table 2. They are ordered by the magnitude of
difference between the median SAUC score for CHART and
conventionally treated patients. At the top of the Table appear the
symptoms where the patients treated with CHART have a higher
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Table 2 Results of SAUC analysis for the RSCL symptoms (exploratory data set)
Median Interquartile range Difference
Symptom CHART Conventional CHART Conventional between Mann–Whitney
medians P-value
Constipation 0.62 0.35 0.15–1.15 0–1.04 0.27 0.018a
Tiredness 1.25 1.12 0.88–1.73 0.85–1.88 0.13 0.821
Feeling tense 0.58 0.46 0.12–1.00 0.12–1.00 0.12 0.456
Nervousness 0.38 0.27 0–0.88 0–1.00 0.11 0.322
Lack of energy 1.12 1.04 0.73–1.73 0.81–1.68 0.08 0.763
Difficulty concentrating 0.30 0.23 0–0.90 0–0.96 0.07 0.300
Pain 1.00 0.94 0.62–1.50 0.38–1.46 0.06 0.310
Difficulty sleeping 0.75 0.69 0.27–1.23 0.15–1.19 0.06 0.281
Depressed mood 0.50 0.46 0.12–1.00 0–1.00 0.04 0.411
Sore mouth/pain on swallowing 1.42 1.38 0.98–1.98 0.96–2.25 0.04 0.698
Shortness of breath 0.27 0.23 0–0.88 0–0.92 0.04 0.607
Restlessness 0.65 0.62 0.20–1.02 0.23–1.00 0.03 0.413
Headaches 0.15 0.15 0–0.54 0–0.62 0 0.707
Worrying 0.73 0.73 0.27–1.27 0.23–1.12 0 0.418
Sore muscles 0.27 0.27 0–0.75 0–0.65 0 0.296
Vomiting 0 0 0–0.33 0–0.35 0 0.160
Dizziness 0 0 0–0.33 0–0.35 0 0.831
Diarrhoea 0 0 0–0 0–0 0 0.555
Tingling hands or feet 0 0 0–0.26 0–0.35 0 0.505
Loss of hair 0 0 0–0.27 0–0.27 0 0.890
Burning eyes 0 0 0–0.15 0–0.17 0 0.724
Coughing up blood 0 0 0–0.27 0–0.23 0 0.419
Shivering 0 0 0–0.38 0–0.38 0 0.469
Despondent feelings 0.46 0.46 0–1.12 0–1.00 0 0.441
Anxious feelings 0.65 0.65 0.23–1.12 0.15–1.00 0 0.928
Nausea 0.15 0.19 0–0.54 0–0.69 –0.04 0.664
Irritability 0.66 0.73 0.27–1.17 0.25–1.00 –0.07 0.526
Lack of appetite 0.88 1.00 0.54–1.58 0.35–1.92 –0.12 0.928
Dry mouth 1.38 1.50 0.88–2.08 1.00–2.25 –0.12 0.060
Heartburn 0 0.15 0–0.38 0–0.65 –0.15 0.045a
Decreased sexual interest 0.73 1.00 0–1.65 0.23–1.92 –0.27 0.082
Cough 0.77 1.12 0.27–1.15 0.50–1.58 –0.35 0.007a
Hoarseness 1.12 1.50 0.50–1.66 0.88–2.00 –0.38 0.003a
aTo be tested in the confirmatory data set.1200 GO Griffiths et al
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SAUC score than conventionally treated patients. At the bottom of
the Table appear the symptoms where conventionally treated
patients have the higher SAUC score. The higher the score the
worse the symptom is over the initial 3 months. For each symptom
the median score by treatment is given together with its inter-
quartile range and the P-value from the Mann–Whitney test.
For the majority of symptoms, there was no good evidence of a
large difference between the two treatments over the initial 3
months. However, there were four symptoms where there was an
apparent difference which therefore generated the following treat-
ment difference hypotheses:
1. Constipation scores are higher for patients in the CHART group
2. Heartburn scores are higher for patients in the conventional
group
3. Cough scores are higher for patients in the conventional group
4. Hoarseness scores are higher for patients in the conventional
group.
Short-term anxiety and depression from HADS. There
were 271 patients (159 CHART, 112 conventional) in the analysis
of anxiety. The median SAUC score was 0 for patients both on
CHART and on conventional treatment, with the interquartile
ranges being 0–0.38 and 0–0.35 respectively. There was no good
evidence of a difference in anxiety for patients in the two treatment
arms over the first 3 months (P = 0.784).
There were 273 patients (160 CHART, 113 conventional) in the
analysis of depression. The median SAUC score was 0 for patients
both on CHART and on conventional radiotherapy, with the
interquartile ranges being 0–0.35 and 0–0.27 respectively. There
was no good evidence of a difference in depression for patients in
the two treatment arms over the first 3 months (P = 0.214).
Group-based analysis
Short-term symptoms from the RSCL. Profiles of the pro-
portion of patients reporting ‘moderately’ or ‘very much’ for those
symptoms exhibiting a difference of the order of 15% between
treatment groups at any given time point are shown in Figure 2.
Note that since the proportions at each assessment were not based
on the same patients, consecutive data points should strictly not be
connected in each of the plots. Numbers of patients contributing at
each timepoint are given underneath each plot. These generated
the following treatment difference hypotheses:
1. Three symptoms were reported as ‘moderately’ or ‘very much’
by more patients in the CHART group at day 21 compared to
the conventional group. These symptoms and percentages
were: the symptom tiredness, 55% of CHART patients and
35% of conventionally treated patients; the symptom pain,
53% of CHART patients and 34% of conventionally treated
patients; the symptom lack of energy, 45% of CHART patients
and 29% of conventionally treated patients. Comparing the
figures at day 21 using the c2 test gave c2 = 10.64 on 1 df for
tiredness (P = 0.001), c2 = 9.995 on 1 df for pain (P = 0.002),
and c2 = 7.399 on 1 df for lack of energy (P = 0.007).
2. Two symptoms were reported as ‘moderately’ or ‘very much’
by more patients in the conventional radiotherapy group at 6
weeks compared to the CHART group. These were: the
symptom cough, 35% of conventionally treated patients and
16% of CHART treated patients; the symptom hoarseness,
55% of conventionally treated patients and 28% of CHART
treated patients. Comparing the figures at 6 weeks using
the c2 test gave c2 = 13.289 on 1 df for cough (P < 0.001),
and c2 = 20.799 on 1 df for hoarseness (P < 0.001).
Short-term anxiety and depression from HADS. Anxiety
and depression levels did not change greatly in the short-term from
those observed at the pre-treatment assessment, remaining at
around 20–25% for each group, and there was no clear evidence of
a large difference between treatments at any time.
Confirmatory data set
In the confirmatory data set, analyses were only performed for
those symptoms where a hypothesis had been generated from the
exploratory data set.
Subject-specific analysis
Unconfirmed hypotheses. There is no evidence to confirm
that: scores for constipation were higher for CHART patients
(P = 0.918); scores for heartburn were higher for conventionally
treated patients (P = 0.815); scores for cough were higher for
conventionally treated patients (P = 0.864), or that scores for
hoarseness were higher for conventionally treated patients
(P = 0.541).
Group-based analysis
Confirmed hypotheses. Pain: There is evidence to confirm
that this symptom was worse for patients on CHART at day 21
compared to patients on conventional radiotherapy (P < 0.0001).
63% of patients on CHART reported ‘moderately’ or ‘very much’
at day 21, with 39% for conventional radiotherapy (Figure 3).
Cough: There is evidence to confirm that this symptom was
worse for patients in the conventional radiotherapy group at 6
weeks compared to the CHART group (P = 0.006). Thirteen per
cent of patients on CHART reported ‘moderately’ or ‘very much’
at 6 weeks, with 26% for conventional radiotherapy.
Hoarseness: There is evidence to confirm that this symptom
was worse for patients in the conventional radiotherapy group at
6 weeks compared to the CHART group (P < 0.001). 32% of
patients on CHART reported ‘moderately’ or ‘very much’ at 6
weeks, with 53% for conventional radiotherapy.
Unconfirmed hypotheses. There is no evidence to confirm
that tiredness (P = 0.398) or lack of energy (P = 0.105) were worse
for CHART patients at day 21.
Long-term QOL
A total of 467 patients survived 1 year or more, of whom 367
(79%) completed their questionnaire at the 1-year assessment
(227 CHART, 140 conventional). Three hundred and eight
patients were expected to return their questionnaires at the 2-year
assessment, of which 221 (72%) were completed (140 CHART,
81 conventional).
Symptoms from the RSCL
Of the patients who completed their questionnaire, 1-year data
were available for 32 of the 33 items on the RSCL for at least 97%QOL in the CHART trial 1201
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of patients (355/367), the exception being decreased sexual
interest where data were available for only 77% of patients
(282/367). At 2 years, data were available for 32 of the 33 items
for at least 96% of patients (213/221), the exception being
decreased sexual interest where data were available for 77%
(170/221). The percentage of patients reporting symptoms as
‘moderately’ or ‘very much’ at 1 year and 2 years are presented in
Figure 4.
At 1 year the largest and only significant difference between
treatments was for decreased sexual interest, which was worse for
conventionally treated patients compared to those treated with
CHART (20% vs 33%, c2 = 6.378, P = 0.012). At 2 years the
largest and only evidence of a difference between treatments was
for sore muscles, which was worse for conventionally treated
patients compared to those treated with CHART (5% vs 15%,
c2 = 6.618, P = 0.010).
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Figure 2 Percentage of patients reporting symptoms from the RSCL as ‘moderately’ or ‘very much’ at each assessment up to 3 months, based on all available
data (exploratory data set) – those symptoms where there is an apparent differenceHowever, it should be noted that with the limited number of
patients with long-term data we could only reliably pick up differ-
ences of the order of 15% at 1 year (50% vs 65%, two-sided,
power > 90%, a = 5%) and 20% at 2 years (50% vs 70%, two-
sided, power = 90%, a = 5%).
Anxiety and depression from HADS
Anxiety scores were available for 97% of patients (355/367) who
completed their questionnaire at the 1-year assessment and 95% of
patients (210/221) at the 2-year assessment. Depression scores
were available for 97% of patients who completed their question-
naire at 1 year and 2 years (357/367 and 215/221 respectively).
Anxiety and depression levels were reasonably similar to those
observed at pre-treatment, and there were no large differences
between treatments at 1 year or at 2 years.
DISCUSSION
In the treatment of patients with head and neck cancer, the use of
CHART resulted in no evidence of a benefit in survival compared
1202 GO Griffiths et al
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Figure 3 Percentage of patients reporting symptoms from the RSCL as ‘moderately’ or ‘very much’ at each assessment up to 3 months, based on all available
data (confirmatory data set). For symptoms in which a difference was hypothesized from the exploratory data setto conventional radiotherapy (P = 0.62, hazard ratio = 1.05, 95%
confidence interval (CI) 0.87–1.25) (Dische et al, 1997). A health
economic assessment suggested that the additional cost of giving
CHART is in the region of £1100 for each patient (Coyle and
Drummond, 1997). Therefore the patients’ assessment of their
own QOL is important in determining whether CHART offers
some advantages which would be an important factor in deter-
mining the appropriate treatment for such patients.
In summary, our analyses have shown evidence of significantly
worse symptoms of pain at day 21 in those treated with CHART
and significantly worse symptoms of cough and hoarseness at 6
weeks in those treated conventionally. There was also evidence to
suggest a greater reporting of decreased sexual interest at 1 year
and sore muscles at 2 years in those treated conventionally;
however, the analysis at these long-term time points were
exploratory in nature and therefore firm conclusions cannot be
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Figure 4 Percentage of patients reporting symptoms from RSCL as ‘moderately’ or ‘very much’ in the long-termreached from these observed differences. These differences at day
21 and 6 weeks are from single time point analyses, the SAUC
analyses suggest that these differences at single time points are
diluted over the 3 months such that over this 3-month period there
was no clear evidence of poorer or better symptoms on CHART.
There are no standard methods in analysing QOL, and probably
the most appropriate recommendation is to analyse the data in
several ways, and only be confident if the results are consistent
(Hopwood et al, 1994). The group-based approach highlights any
differences in treatments which may be occurring in the patient
group as a whole at defined points in time. Although useful, such
an approach does not allow for the large degree of variability
between patients over time, nor does it necessarily reflect the
changing patterns of symptoms over time. To allow for this in the
analysis a subject-specific approach is also used.
It is interesting how in the subject-specific analysis, after
randomly splitting the data into two data sets, significant differ-
ences were found for four symptoms (constipation, cough, hoarse-
ness and heartburn) between the two arms in the exploratory data
set, which were not confirmed in the confirmatory data set. This
strengthens the reasoning for splitting the data into two sets, other-
wise multiple comparisons may have resulted in an inappropriate
interpretation. The method we used here of one data set to generate
hypotheses and one to confirm them, means that we have a greater
degree of confidence in any differences found.
In our analyses we found significant differences in anxiety
between sexes at the pre-treatment assessment (P < 0.001) with
24% of males presenting with borderline or case anxiety compared
with 43% of females. The NSCLC paper also found a significant
difference with 14% of males presenting borderline or case
anxiety compared with 45% of females (P < 0.0001). These results
and proportions are consistent with those with anxiety disorder
expected in the general population (Murphy et al, 1988). There
was a non-significant difference in depression between sexes
(P = 0.095).
In the parallel NSCLC trial the group-based analysis of the
short-term data resulted in more severe sore mouth or pain on
swallowing and heartburn at day 21 for those treated with CHART.
This analysis of the head and neck trial reported worse symptoms
for CHART at day 21, which may reflect the fact that CHART
treatment had recently finished whereas the conventional group
were just halfway through their course. This effect at the end of a
treatment period is supported by the finding that there were worse
symptoms of cough and hoarseness in the conventionally treated
patients at 6 weeks, when that course of treatment ends. Both trials
were similar in that the subject-specific analysis did not imply any
differences in symptoms over the first 3 months. Long-term
analyses in both trials were only exploratory in nature but did
suggest worse symptoms of pain (NSCLC trial), decreased sexual
interest and sore muscles (head and neck trial) in the convention-
ally treated patients. Both trials found no evidence of any differ-
ences between the CHART and conventional treatments in terms
of anxiety and depression.
In our analyses we found evidence of worse symptoms of cough
and hoarseness at 6 weeks in the conventionally treated patients.
These two symptoms are often related and one may speculate that
these symptoms are more likely to be disease related rather than
treatment related. However, we must emphasize that this analysis
includes both causes of such symptoms as we do not try to distin-
guish between them.
The overall conclusion of the analysis of these data from the
head and neck trial is that in the short-term there was no evidence
of any differences in psychological symptoms between conven-
tionally treated patients and those treated with CHART. In addi-
tion, there was found to be no evidence of a difference in the
physical symptoms between conventionally treated patients and
those treated with CHART except for worse symptoms of pain at
day 21 for those on CHART and worse symptoms of cough and
hoarseness at 6 weeks for those treated conventionally. These
differences subsided by 3 months.
The physical symptoms in this study correspond reasonably
well with what might have been predicted from the peak acute
reactions, illness and tumour response rate as reported on the clin-
ical forms, being somewhat increased, but in shorter duration, in
the CHART group. The symptoms of anxiety and depression did
not differ in the two treatment groups, suggesting that they may be
related to underlying disease rather than therapy. The analysis of
patient reported symptoms does not give clear indication that one
regimen is superior to the other in terms of ‘quality of life’, with
the more severe reaction in the CHART group being offset by the
longer duration of symptoms in the conventionally treated group.
The QOL data seem to closely follow the information collected by
the clinicians on the clinical forms. This raises the question as to
how far such detailed QOL studies provide information of addi-
tional benefit in deciding optimal treatment. Only further experi-
ence and analysis in other trials will reveal whether this is a
common finding.
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